These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 30261804)

  • 1. Estimating age group-dependent sensitivity and mean sojourn time in colorectal cancer screening.
    Sung NY; Jun JK; Kim YN; Jung I; Park S; Kim GR; Nam CM
    J Med Screen; 2019 Mar; 26(1):19-25. PubMed ID: 30261804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Colorectal cancer mass-screening: estimation of faecal occult blood test sensitivity, taking into account cancer mean sojourn time.
    Launoy G; Smith TC; Duffy SW; Bouvier V
    Int J Cancer; 1997 Oct; 73(2):220-4. PubMed ID: 9335446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estimating key parameters in FOBT screening for colorectal cancer.
    Wu D; Erwin D; Rosner GL
    Cancer Causes Control; 2009 Feb; 20(1):41-6. PubMed ID: 18704710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estimating sensitivity and sojourn time in screening for colorectal cancer: a comparison of statistical approaches.
    Prevost TC; Launoy G; Duffy SW; Chen HH
    Am J Epidemiol; 1998 Sep; 148(6):609-19. PubMed ID: 9753016
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of systematic false-negative test results on the performance of faecal occult blood screening.
    Loeve F; Boer R; van Oortmarssen GJ; van Ballegooijen M; Habbema JD
    Eur J Cancer; 2001 May; 37(7):912-7. PubMed ID: 11313180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicting the effectiveness of the Finnish population-based colorectal cancer screening programme.
    Chiu SY; Malila N; Yen AM; Chen SL; Fann JC; Hakama M
    J Med Screen; 2017 Dec; 24(4):182-188. PubMed ID: 28084889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of screening data: colorectal cancer.
    Gyrd-Hansen D; Søgaard J; Kronborg O
    Int J Epidemiol; 1997 Dec; 26(6):1172-81. PubMed ID: 9447396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sojourn time of preclinical colorectal cancer by sex and age: estimates from the German national screening colonoscopy database.
    Brenner H; Altenhofen L; Katalinic A; Lansdorp-Vogelaar I; Hoffmeister M
    Am J Epidemiol; 2011 Nov; 174(10):1140-6. PubMed ID: 21984657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes of faecal occult blood tests requested outside the UK National Bowel Cancer Screening Programme.
    McDonald R; Tomlins A; Smith S; Harmston C
    J Clin Pathol; 2013 Apr; 66(4):330-4. PubMed ID: 23288919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Faecal occult blood testing screening for colorectal cancer and 'missed' interval cancers: are we ignoring the elephant in the room? Results of a multicentre study.
    George AT; Aggarwal S; Dharmavaram S; Menon A; Dube M; Vogler M; Field A
    Colorectal Dis; 2017 May; 19(5):O108-O114. PubMed ID: 27992095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunochemical testing of individuals positive for guaiac faecal occult blood test in a screening programme for colorectal cancer: an observational study.
    Fraser CG; Matthew CM; Mowat NA; Wilson JA; Carey FA; Steele RJ
    Lancet Oncol; 2006 Feb; 7(2):127-31. PubMed ID: 16455476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of seasonal variations in ambient temperatures on performance of immunochemical faecal occult blood test for colorectal cancer screening: observational study from the Florence district.
    Grazzini G; Ventura L; Zappa M; Ciatto S; Confortini M; Rapi S; Rubeca T; Visioli CB; Halloran SP
    Gut; 2010 Nov; 59(11):1511-5. PubMed ID: 20603498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estimation of screening test (Hemoccult) sensitivity in colorectal cancer mass screening.
    Jouve JL; Remontet L; Dancourt V; Lejeune C; Benhamiche AM; Faivre J; Esteve J
    Br J Cancer; 2001 Jun; 84(11):1477-81. PubMed ID: 11384097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interval cancers in a guaiac-based colorectal cancer screening programme: Consequences on sensitivity.
    Blom J; Törnberg S
    J Med Screen; 2017 Sep; 24(3):146-152. PubMed ID: 28142309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluating the long-term effect of FOBT in colorectal cancer screening.
    Luo D; Cambon AC; Wu D
    Cancer Epidemiol; 2012 Feb; 36(1):e54-60. PubMed ID: 22075536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tailored telephone counselling to increase participation of underusers in a population-based colorectal cancer-screening programme with faecal occult blood test: A randomized controlled trial.
    Denis B; Broc G; Sauleau EA; Gendre I; Gana K; Perrin P
    Rev Epidemiol Sante Publique; 2017 Feb; 65(1):17-28. PubMed ID: 28089385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Colorectal cancer screening: yield of faecal occult blood testing.
    Teoh ML; Puvan R; Cheah PY; Yuen Y
    Asian Pac J Cancer Prev; 2010; 11(1):153-6. PubMed ID: 20593948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fecal occult blood screening in the Minnesota study: sensitivity of the screening test.
    Church TR; Ederer F; Mandel JS
    J Natl Cancer Inst; 1997 Oct; 89(19):1440-8. PubMed ID: 9326913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A projection of benefits due to fecal occult blood test for colorectal cancer.
    Wu D; Erwin D; Rosner GL
    Cancer Epidemiol; 2009 Oct; 33(3-4):212-5. PubMed ID: 19733140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interval cancers in a community-based programme of colorectal cancer screening with faecal occult blood test.
    Tazi MA; Faivre J; Lejeune C; Bolard P; Phelip JM; Benhamiche AM
    Eur J Cancer Prev; 1999 Apr; 8(2):131-5. PubMed ID: 10335459
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.